Skip to content
DataLookout
Menu

GEMS-PCOSNCT06050265

Glucose Evaluation Through Continuous Glucose Monitors in Polycystic Ovary Syndrome

StatusCompleted
PhaseNot applicable
Primary completion
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

Version history last read from ClinicalTrials.gov on Aug 30, 2026. The record was updated there on Nov 20, 2026; versions filed since then are not listed here yet.

All 4 versions: 3 with changes below, 1 re-verified with no change. See every version on ClinicalTrials.gov ↗

  1. Minor Trial completed
    • Study completion date changed from estimate of Dec 1, 2026 to Jul 12, 2025
  2. Minor Trial status: Recruiting to Active, Not Recruiting
    • Primary completion date changed from estimate of Jul 2025 to Jul 12, 2025
    • Study completion date: Jul 2025 to Dec 1, 2026
    • Site details revised
    v3
  3. Notable Trial status: Not Yet Recruiting to Recruiting
    • Start date: Sep 2023 to Nov 29, 2023
    • Site details revised
    v2
  4. Study First Submitted
  • Notable: the plan changed
  • Minor: routine updates

Endpoints

Primary

Difference between change in hemoglobin A1C
Timeframe: 90 days

Secondary (1)

Difference between change in fasting insulin

Arms and interventions

Intervention arm - CGMExperimental

Participants randomized to intervention arm will be given standard of care nutrition and exercise counseling to optimize weight, nutrition and glycemic status AND will be asked to wear a DEXCOM CGM for 90 days.

Control armNo intervention

Participants randomized to control arm will ONLY be given standard of care nutrition and exercise counseling to optimize weight, nutrition and glycemic status.

Devices: DEXCOM Continuous Glucose Monitor (CGM)

Sites

1 site in 1 country

  • UCSF Center for Reproductive HealthSan Francisco, California, United States